361 Capital LLC cut its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 2.5% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 3,300 shares of the biopharmaceutical company’s stock after selling 84 shares during the quarter. 361 Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $1,355,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in REGN. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $292,457,000. FMR LLC boosted its position in shares of Regeneron Pharmaceuticals by 6.6% in the 4th quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after buying an additional 330,875 shares in the last quarter. Morgan Stanley boosted its position in shares of Regeneron Pharmaceuticals by 70.6% in the 3rd quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after buying an additional 192,236 shares in the last quarter. Parnassus Investments CA purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $65,699,000. Finally, American Century Companies Inc. boosted its position in shares of Regeneron Pharmaceuticals by 16.6% in the 4th quarter. American Century Companies Inc. now owns 1,003,471 shares of the biopharmaceutical company’s stock worth $374,796,000 after buying an additional 142,779 shares in the last quarter. Institutional investors and hedge funds own 67.63% of the company’s stock.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total transaction of $305,930.00. Following the completion of the transaction, the director now owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 141,968 shares of company stock valued at $57,360,056. Corporate insiders own 11.84% of the company’s stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.76 billion. During the same period in the prior year, the company earned $4.67 EPS. The company’s revenue was up 13.3% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current year.
Several research firms recently commented on REGN. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald restated a “hold” rating and issued a $441.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 6th. Piper Jaffray Companies upped their target price on shares of Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a report on Tuesday, February 26th. Guggenheim lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $466.00 to $425.00 in a report on Friday, February 22nd. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 target price on the stock in a report on Thursday, February 7th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $400.82.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/22/361-capital-llc-sells-84-shares-of-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: S&P 500 Index
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.